Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Large Growth in Short Interest

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) was the target of a significant growth in short interest in June. As of June 30th, there was short interest totaling 83,765 shares, a growth of 88.8% from the June 15th total of 44,358 shares. Based on an average daily trading volume, of 30,721 shares, the days-to-cover ratio is presently 2.7 days. Currently, 8.4% of the company’s stock are sold short.

Institutional Trading of Virtus LifeSci Biotech Clinical Trials ETF

An institutional investor recently bought a new position in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC bought a new position in shares of Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned about 0.41% of Virtus LifeSci Biotech Clinical Trials ETF as of its most recent SEC filing.

Virtus LifeSci Biotech Clinical Trials ETF Trading Up 2.1%

BBC traded up $1.06 during trading on Friday, hitting $50.97. The company had a trading volume of 81,795 shares, compared to its average volume of 25,004. The business has a 50-day moving average of $46.47 and a 200-day moving average of $43.50. Virtus LifeSci Biotech Clinical Trials ETF has a 1-year low of $20.87 and a 1-year high of $54.95.

Virtus LifeSci Biotech Clinical Trials ETF Company Profile

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.